Compare iShares MSCI Germany (DAX) (EWG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Pfizer Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.44B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 110.8× iShares MSCI Germany (DAX)'s market cap, and Pfizer Inc pays a 6.14% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Pfizer Inc for 158 Days on average.
| EWG | PFE | |
|---|---|---|
Market Cap | $1.44B | $159.59B |
Volume | 1,258,794 | 30,937,010 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $29.02 |
52-Week Low | $38.08 | $23.67 |
Typical Hold Time | 56 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% today amid bearish technical signals with 19 sell indicators versus 1 buy. The stock faces resistance at $41 with support at $40, while European market sentiment remains cautious due to ECB rate hike expectations and energy price pressures. Key financial ratios are unavailable in the current dataset.
The outlook remains cautious with technical indicators signaling bearish momentum and European macroeconomic headwinds from potential ECB tightening. Investment opportunities depend on resolution of energy inflation concerns, while risks include further rate hikes and deteriorating eurozone business confidence.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
